Assignee
LUDWIG INST CANCER RES
US·396 granted patents·41 pending applications·8,116 citations·filing 1987–2017
Top patents by PatentIndex Score
437 records- 0197US7314721B2Small cell lung cancer associated antigens and uses thereforLUDWIG INST CANCER RES·Filed 2004·Granted Jan 1, 2008·111 cites·10 claims
- 0296US6235713B1Vascular endothelial growth factor-D (VEGF-D) polypeptidesLUDWIG INST CANCER RES·Filed 1997·Granted May 22, 2001·113 cites·16 claims
- 0396US5840693AVascular endothelial growth factor-BLUDWIG INST CANCER RES·Filed 1996·Granted Nov 24, 1998·156 cites·22 claims
- 0496US5698396AMethod for identifying auto-immunoreactive substances from a subjectLUDWIG INST CANCER RES·Filed 1995·Granted Dec 16, 1997·179 cites·16 claims
- 0596US5607918AVascular endothelial growth factor-B and DNA coding thereforLUDWIG INST CANCER RES·Filed 1995·Granted Mar 4, 1997·239 cites·13 claims
- 0696US5530109ADNA encoding glial mitogenic factorsLUDWIG INST CANCER RES·Filed 1993·Granted Jun 25, 1996·136 cites·12 claims
- 0796US5342774ANucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1LUDWIG INST CANCER RES·Filed 1991·Granted Aug 30, 1994·232 cites·18 claims
- 0895US7589180B2Specific binding proteins and uses thereofLUDWIG INST CANCER RES·Filed 2002·Granted Sep 15, 2009·70 cites·4 claims
- 0995US6245530B1Receptor ligandLUDWIG INST CANCER RES·Filed 1996·Granted Jun 12, 2001·143 cites·35 claims
- 1095US5824492APolypeptides having kinase activity, their preparation and useLUDWIG INST CANCER RES·Filed 1993·Granted Oct 20, 1998·127 cites·7 claims
- 1194US7311914B2MAGE-A4 antigenic peptides and uses thereofLUDWIG INST CANCER RES·Filed 2002·Granted Dec 25, 2007·67 cites·11 claims
- 1294US6849420B2Method for determining modulation of p110δ activityLUDWIG INST CANCER RES·Filed 2002·Granted Feb 1, 2005·95 cites·14 claims
- 1394US6689352B2Method for activating only the vascular endothelial growth factor receptor-3 and uses thereofLUDWIG INST CANCER RES·Filed 2001·Granted Feb 10, 2004·55 cites·10 claims
- 1494US6383484B1Antibodies to truncated VEGF-D and thereofLUDWIG INST CANCER RES·Filed 1999·Granted May 7, 2002·115 cites·22 claims
- 1594US5830753AIsolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.LUDWIG INST CANCER RES·Filed 1994·Granted Nov 3, 1998·82 cites·14 claims
- 1694US5716930AGlial growth factorsLUDWIG INST CANCER RES·Filed 1994·Granted Feb 10, 1998·109 cites·4 claims
- 1794US5405940AIsolated nonapeptides derived from MAGE genes and uses thereofLUDWIG INST CANCER RES·Filed 1992·Granted Apr 11, 1995·129 cites·9 claims
- 1893US7034105B2FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapyLUDWIG INST CANCER RES·Filed 2001·Granted Apr 25, 2006·47 cites·15 claims
- 1993US6689580B1Growth factorLUDWIG INST CANCER RES·Filed 1999·Granted Feb 10, 2004·59 cites·14 claims
- 2093US6274710B1Antibodies which specifically bind T Cell inducible factors (TIFs)LUDWIG INST CANCER RES·Filed 1998·Granted Aug 14, 2001·94 cites·8 claims
- 2192US7381801B2Chimerized GM-CSF antibodiesLUDWIG INST CANCER RES·Filed 2003·Granted Jun 3, 2008·28 cites·3 claims
- 2292US6605443B1Method for identifying compounds that affect Smad7 bindingLUDWIG INST CANCER RES·Filed 2001·Granted Aug 12, 2003·35 cites·7 claims
- 2392US6482623B1Lipid kinaseLUDWIG INST CANCER RES·Filed 1997·Granted Nov 19, 2002·140 cites·20 claims
- 2492US5681751AMethod allowing sequential chemical reactionsLUDWIG INST CANCER RES·Filed 1995·Granted Oct 28, 1997·107 cites·20 claims
- 2591US9700532B2iNKT cell modulators and methods of using the sameLUDWIG INST CANCER RES·Filed 2016·Granted Jul 11, 2017·11 cites·48 claims
- 2691US7696204B2Pharmaceutical compoundsLUDWIG INST CANCER RES·Filed 2006·Granted Apr 13, 2010·27 cites·7 claims
- 2791US6605711B1NY-ESO-1 peptide derivatives, and uses thereofLUDWIG INST CANCER RES·Filed 2000·Granted Aug 12, 2003·39 cites·21 claims
- 2891US6403373B1Isolated nucleic acid molecules associated with colon, renal, and stomach cancer and methods of using theseLUDWIG INST CANCER RES·Filed 1998·Granted Jun 11, 2002·86 cites·29 claims
- 2991US5571711AIsolated nucleic acid molecules coding for BAGE tumor rejection antigen precursorsLUDWIG INST CANCER RES·Filed 1993·Granted Nov 5, 1996·69 cites·11 claims
- 3090US6965010B2Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteinsLUDWIG INST CANCER RES·Filed 2001·Granted Nov 15, 2005·29 cites·50 claims
- 3190US6391302B1Method for treating cancers which present antigen FB5 with humanized antibodiesLUDWIG INST CANCER RES·Filed 2000·Granted May 21, 2002·18 cites·14 claims
- 3290US6359117B1Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereforLUDWIG INST CANCER RES·Filed 1999·Granted Mar 19, 2002·73 cites·3 claims
- 3390US6338947B1Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewithLUDWIG INST CANCER RES·Filed 2000·Granted Jan 15, 2002·33 cites·15 claims
- 3490US5620886AIsolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2LUDWIG INST CANCER RES·Filed 1993·Granted Apr 15, 1997·75 cites·13 claims
- 3590US5612201AIsolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursorLUDWIG INST CANCER RES·Filed 1994·Granted Mar 18, 1997·127 cites·3 claims
- 3690US5342757AMonoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereofLUDWIG INST CANCER RES·Filed 1992·Granted Aug 30, 1994·69 cites·10 claims
- 3789US6692925B1Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their useLUDWIG INST CANCER RES·Filed 1999·Granted Feb 17, 2004·110 cites·7 claims
- 3889US6342587B1A33 antigen specific immunoglobulin products and uses thereofLUDWIG INST CANCER RES·Filed 1999·Granted Jan 29, 2002·93 cites·15 claims
- 3989US5928939AVascular endothelial growth factor-b and dna coding thereforLUDWIG INST CANCER RES·Filed 1995·Granted Jul 27, 1999·65 cites·29 claims
- 4089US5648226AIsolated peptides derived from tumor rejection antigens, and their useLUDWIG INST CANCER RES·Filed 1995·Granted Jul 15, 1997·72 cites·6 claims
- 4188US7049413B2MAGE-A3 peptides presented by HLA class II moleculesLUDWIG INST CANCER RES·Filed 2001·Granted May 23, 2006·11 cites·19 claims
- 4288US6794501B2Colon cancer antigen panelLUDWIG INST CANCER RES·Filed 2001·Granted Sep 21, 2004·34 cites·14 claims
- 4387US6946543B2Truncated EGF receptorLUDWIG INST CANCER RES·Filed 2001·Granted Sep 20, 2005·34 cites·23 claims
- 4487US6652853B2Method for treating cancer using A33 specific antibodies and chemotherapeutic agentsLUDWIG INST CANCER RES·Filed 2001·Granted Nov 25, 2003·28 cites·28 claims
- 4587US6346249B1Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin productsLUDWIG INST CANCER RES·Filed 2000·Granted Feb 12, 2002·13 cites·19 claims
- 4687US6331301B1Antibodies specific for vascular endothelial growth factor-BLUDWIG INST CANCER RES·Filed 1997·Granted Dec 18, 2001·58 cites·5 claims
- 4787US5516698AMethods and apparatus allowing sequential chemical reactionsLUDWIG INST CANCER RES·Filed 1991·Granted May 14, 1996·63 cites·4 claims
- 4887US5229495ASubstantially pure receptor like TGF-β 1 binding molecules and uses thereofLUDWIG INST CANCER RES·Filed 1991·Granted Jul 20, 1993·64 cites·5 claims
- 4986US6730489B1Antibodies to truncated VEGF-D and uses thereofLUDWIG INST CANCER RES·Filed 2002·Granted May 4, 2004·20 cites·20 claims
- 5086US6548064B1Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA moleculesLUDWIG INST CANCER RES·Filed 1999·Granted Apr 15, 2003·51 cites·6 claims
Showing the top 50 of 437 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when LUDWIG INST CANCER RES files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →